SummitTX Capital’s Arcellx ACLX Stock Holding History

SummitTX Capital’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,448	Closed	-$2.09M	–	677
2025 Q3	$2.09M	Buy	+25,448	New	+$1.83M	0.09%	254

Other funds holding ACLX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SummitTX Capital's ACLX Position: Q4 2025 in Review

SummitTX Capital sold out of Arcellx (ACLX) in Q4 2025, closing a stake of 25,448 shares — an estimated $2.09M sold.

SummitTX Capital first reported a position in ACLX in Q3 2025 and held it in 1 quarter. The position peaked at $2.09M in Q3 2025. 218 funds tracked by Wall St. Rank hold ACLX as of Q4 2025.

SummitTX Capital reported no remaining Arcellx position as of Q4 2025 after selling out during the quarter.
SummitTX Capital sold 25,448 Arcellx shares in Q4 2025, an estimated $2.09M.
SummitTX Capital first reported a position in Arcellx in Q3 2025 and held it in 1 quarter.
SummitTX Capital's Arcellx position peaked at $2.09M in Q3 2025.
218 funds tracked by Wall St. Rank held Arcellx as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.